AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 18, 2026 Arcus Biosciences will participate in the 8th Annual Evercore Healthcare Conference on December 1st, 2026 and Citi's 2026 Global Healthcare Conference on December 2nd, 2026. AI-generated summary · Source: company release
NYSE: $RCUSBiotech · OncologyClinical, financing and dilution risk

RCUS Stock Hub: Arcus Biosciences News, Casdatifan and Quemliclustat

Arcus reported $694M of September cash and securities, followed by $269.7M net from its October offering. PRISM-1 interim analysis is expected in Q4 2026, while casdatifan advances through Phase 3 development. The Gilead relationship has narrowed, and growth of the independent portfolio brings funding and execution demands. Q3 2026 Form 10-Q · November 4 October equity offering closed · October 23 Q3 results and pipeline update · November 4

Last updated: November 18, 2026Financial period: September 30, 2026Currency: USD
Research Library · Biotech
Arcus Biosciences: Casdatifan, PRISM-1 and the Independent Development Strategy
Clinical evidence, Gilead rights and post-financing resources · Research as of November 12, 2026
Get the report (PDF)
Next catalyst · company-guided analysis window
Q4 2026 · PRISM-1 interim analysis

The fully enrolled Phase 3 study tests quemliclustat with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer. A planned interim analysis is not a promise of immediate public topline or a fixed announcement date. Q3 results and pipeline update · November 4

Also scheduled: fireside chats at the 8th Annual Evercore Healthcare Conference on December 1 at 3:50 p.m. ET and at Citi’s 2026 Global Healthcare Conference on December 2 at 2:20 p.m. ET, with live webcasts on the Arcus investor site. PEAK-20 initiation remains expected by year-end. Conference schedule · November 18 Q3 results and pipeline update · November 4
RCUS daily price chart
Daily chart · Finviz (affiliate link on click). Explore RCUS on JC Just Charts.

RCUS stock data: financial position and capital

Chart analysis · JC
Technical chart analysis of $RCUS with bull and bear scenarios on JC Just Charts.
Cash + securities
$694M
September 30 reported balance
October net proceeds
$269.7M
Offering closed October 23
Q3 R&D
$117M
Net of partner reimbursements
Q3 net loss
$128M
Quarter ended September 30
Common shares
143.991M
October 29 cover; includes financing
Company funding outlook
Into 2029
November forecast including October offering

Financial figures in USD. September cash and securities are not a post-offering balance. The company has no product-sales revenue; Q3 collaboration revenue was $9M. Q3 2026 Form 10-Q · November 4 Q3 results and pipeline update · November 4 October equity offering closed · October 23

RCUS stock: funded development, with randomized evidence still ahead

ARC-20 early cohorts do not establish randomized superiority. PRISM-1 analysis timing, enrollment completion and public results are separate milestones. Q3 results and pipeline update · November 4

▲ The constructive case

Casdatifan retains independent Arcus economics outside Taiho territories. October financing supports development and management funding guidance into 2029; several clinical milestones can add information. Q3 2026 Form 10-Q · November 4 Q3 results and pipeline update · November 4

▼ The cautious case

The company remains loss-making and clinical-stage. Collaboration scope has narrowed, domvanalimab studies are winding down, and financing plus equity awards dilute ownership. Q3 2026 Form 10-Q · November 4

Latest RCUS news

Nov 18, 2026

Arcus Biosciences to participate in two upcoming investor conferences

Arcus Biosciences announced that its management team will participate in fireside chats and one-on-one meetings at two upcoming December investor conferences. The 8th Annual Evercore Healthcare Conference is on Tuesday, December 1st, 2026, in Coral Gables, FL, and Citi's 2026 Global Healthcare Conference is on Wednesday, December 2nd, 2026, in Miami, FL. Live webcasts of the fireside chats will be available on the Investors & Media section of the company website, with replays available after each live event.

Nov 4, 2026

Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus Biosciences reported third-quarter 2026 results for the quarter ended September 30, 2026. Cash, cash equivalents and marketable securities were $694 million, which together with $288 million gross proceeds from its October equity financing is expected to fund operations into 2029. Revenues were $9 million, compared with $26 million a year earlier, and the net loss was $128 million, compared with $135 million. Arcus expects to initiate the PEAK-20 Phase 3 study in the fourth quarter of 2026 and expects PEAK-1 enrollment to complete in the next two to three months.

RCUS stock catalysts: PRISM-1 and casdatifan Phase 3 development

Registry estimated completions are not issuer-announced readout dates. Casdatifan and quemliclustat remain investigational in the Arcus development portfolio. Q3 2026 Form 10-Q · November 4 Q3 results and pipeline update · November 4

Casdatifan and quemliclustat: different evidence packages

ARC-20 used a September 4 cutoff. First-line casdatifan/zimberelimab: n=30, cORR 50%, 12-month PFS 69%. Triplet: 31 treated, 24 with a first scan, one primary progression. Second-line casdatifan/cabozantinib: n=43, median PFS 14.5 months. Later-line monotherapy: 121 pooled patients, median OS 35 months. These are early cohort observations with different follow-up. Q3 2026 Form 10-Q · November 4 Q3 results and pipeline update · November 4

PEAK-1 is randomized; PEAK-20 plans casdatifan/ipilimumab/nivolumab, a different PD-1 antibody from the early triplet. PRISM-1 tests quemliclustat plus chemotherapy in metastatic pancreatic cancer and is fully enrolled. AB102 is in healthy volunteers, not a completed urticaria-efficacy study. Q3 results and pipeline update · November 4 AB102 healthy volunteers trial record

Arcus and Gilead: licenses, options and retained casdatifan rights

The broad collaboration term ended July 14 after the continuation payment was not made. Existing licenses include quemliclustat, zimberelimab, domvanalimab and AB308; specified options survive. AB102 options expired in May. Casdatifan is owned by Arcus with Taiho regional rights. Q3 2026 Form 10-Q · November 4

Gilead relinquished its three board-designation rights and seats in Q3; the disclosed 24.6% holding is dated September 30, before the October offering. PRISM-1 funding has specific exceptions to generic cost-sharing. Q3 2026 Form 10-Q · November 4

RCUS cash, debt and share dilution

Nine-month operating cash use was $345M and net loss $347M. The October offering closed with 16,428,572 shares at $17.50, producing $269.7M net. The October 29 common count already includes those shares. Q3 2026 Form 10-Q · November 4 October equity offering closed · October 23

Hercules principal was $100M, with carrying value $102M and conditional undrawn tranches. September potentially dilutive securities excluded from loss-per-share calculations totaled 21.3M at rounded filing precision. Q3 2026 Form 10-Q · November 4

Merlintrader Health Score · RCUS

3.20out of 5
Financial position3.5

September cash and securities were $694M, followed by $269.7M net October financing. Management guides funding into 2029; operating cash use remains substantial and loan principal is $100M. Q3 2026 Form 10-Q · November 4 October equity offering closed · October 23 Q3 results and pipeline update · November 4

Catalysts3.5

PRISM-1 interim analysis is expected Q4 2026; casdatifan Phase 3 and additional 2027 data provide several milestones. Analysis, enrollment and public readout are distinct events. The December 1 and December 2 conference fireside chats are investor events, not data releases. Q3 results and pipeline update · November 4

Dilution2.0

The completed October offering issued 16,428,572 shares. September potential securities excluded from diluted loss per share total 21.3M at rounded filing precision. Q3 2026 Form 10-Q · November 4 October equity offering closed · October 23

Trading liquidity4.0

An established NYSE listing with an active daily price history; clinical and financing disclosures can change trading conditions.

Execution3.0

Casdatifan development and funding have advanced, while domvanalimab studies wind down and no product-sales franchise is established. Q3 2026 Form 10-Q · November 4 Q3 results and pipeline update · November 4

Weighted calculation: 3.5 × 30% + 3.5 × 30% + 2.0 × 20% + 4.0 × 10% + 3.0 × 10% = 3.20 out of 5. Editorial assessment as of November 12, 2026; reviewed November 18, 2026 after Arcus scheduled the December 1 and December 2 conference fireside chats, with all scores unchanged. Weights: financial position 30%, catalysts 30%, dilution 20%, trading liquidity 10%, execution 10%. Not an investment recommendation or probability of clinical success.

RCUS red flags

RCUS Stock FAQ: Arcus Biosciences Questions Answered

When is the next RCUS stock catalyst?

As of November 18, 2026, Arcus expects the PRISM-1 interim analysis in Q4 2026. The analysis window is not a fixed public-results date. PEAK-20 initiation is expected by year-end; PEAK-1 enrollment completion is expected two to three months after November 4. Management is scheduled to hold fireside chats at the Evercore Healthcare Conference on December 1 (3:50 p.m. ET) and at Citi’s Global Healthcare Conference on December 2 (2:20 p.m. ET); these are investor events, not data releases. Q3 results and pipeline update · November 4 Conference schedule · November 18

Are Arcus Biosciences casdatifan and quemliclustat FDA approved?

As of November 12, 2026, casdatifan and quemliclustat remain investigational in Arcus development programs and are not FDA-approved commercial products. Arcus has not generated product-sales revenue. Zimberelimab has separate Chinese approvals through Gloria, which do not authorize the Arcus combinations. Q3 2026 Form 10-Q · November 4 Q3 results and pipeline update · November 4 Arcus disclosure of zimberelimab territorial approvals · 2024

How much cash does Arcus Biosciences have?

At September 30, 2026, Arcus held $694M in cash and marketable securities. The October offering later generated approximately $269.7M net. Management guides funding into 2029 using its existing plan; the offering proceeds are separate from the September reported balance. Q3 2026 Form 10-Q · November 4 October equity offering closed · October 23 Q3 results and pipeline update · November 4

Did Arcus Biosciences issue more RCUS shares?

On October 23, 2026, Arcus closed an offering of 16,428,572 shares at $17.50. The October 29 cover count of 143,990,614 common shares already includes the financing. September options, RSUs and purchase-plan interests also create potential economic dilution. October equity offering closed · October 23 Q3 2026 Form 10-Q · November 4

When did Arcus Biosciences report Q3 2026 earnings?

Arcus reported Q3 2026 results on November 4, 2026. Collaboration revenue was $9M, R&D expense $117M and net loss $128M. The company expects $70–75M of 2026 GAAP revenue; this is collaboration accounting rather than approved-product sales. Q3 results and pipeline update · November 4 Q3 2026 Form 10-Q · November 4

What does Arcus Biosciences do?

As of November 12, 2026, Arcus develops cancer and immune-disease therapies. Casdatifan targets HIF-2α in kidney cancer, quemliclustat targets CD73 in pancreatic cancer, and AB102 is an early MRGPRX2 immunology program. Arcus remains clinical-stage. Q3 2026 Form 10-Q · November 4 Q3 results and pipeline update · November 4

Does Gilead own Arcus Biosciences casdatifan?

As of September 30, 2026, Arcus solely owns casdatifan, subject to Taiho rights in specified Asian territories. The broad Gilead collaboration term ended July 14, but certain licenses and time-limited options remain. Casdatifan is not among Gilead licensed assets. Q3 2026 Form 10-Q · November 4

What did Arcus Biosciences ARC-20 show?

The October 2026 update reported casdatifan data with a September 4 cutoff, including 121 pooled later-line monotherapy patients and a 43-patient second-line combination cohort. These early cohort observations are not randomized proof of superiority over separate treatment benchmarks. Q3 2026 Form 10-Q · November 4 Q3 results and pipeline update · November 4

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $RCUS or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, ClinicalTrials.gov and market data, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Clinical-stage biotechnology companies carry high execution, regulatory and financing risk. Trials fail, endpoints miss, enrollment slips, regulators ask for more data or decline to file an application, and companies that spend ahead of revenue raise equity at whatever price the market will bear. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate. Investors may lose part or all of their capital.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.